Cargando…

Targeting CD22 for the Treatment of B-Cell Malignancies

Immunotherapeutic agents play an increasingly important role in the treatment of B-cell malignancies. CD19 and CD20 are common targets for lymphoid malignancies, though patients who relapse have few therapeutic options remaining. CD22 is a cell surface sialoglycoprotein uniquely present on B-cells a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Nikesh N, Sokol, Lubomir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275043/ https://www.ncbi.nlm.nih.gov/pubmed/34262884 http://dx.doi.org/10.2147/ITT.S288546

Ejemplares similares

Targeting CD22 for B-cell hematologic malignancies
por: Xu, Jia, et al.
Publicado: (2023)

Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma
por: Kelling, Matthew, et al.
Publicado: (2018)

Hematological Malignancies and Arterial Thromboembolism
por: Visweshwar, Nathan, et al.
Publicado: (2019)

Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies
por: Müller, Fabian, et al.
Publicado: (2017)

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
por: Spiegel, Jay Y., et al.
Publicado: (2021)

Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
por: Aranda-Orgilles, Beatriz, et al.
Publicado: (2023)

Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes
por: Fiorina, Paolo, et al.
Publicado: (2008)

Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Zhang, Yumeng, et al.
Publicado: (2022)

Hepatic Infiltration with Malignant T-cells Manifesting as Impending Acute Liver Failure in Sezary Syndrome
por: Zhang, Yumeng, et al.
Publicado: (2020)

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
por: Testa, Ugo, et al.
Publicado: (2019)

Hepatitis B Reactivation with Novel Agents in Non-Hodgkin’s Lymphoma and Prevention Strategies
por: Ozoya, Oluwatobi O., et al.
Publicado: (2016)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021)

Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells
por: Fuh, Franklin K, et al.
Publicado: (2017)

Effectiveness and safety of CD22 and CD19 dual‐targeting chimeric antigen receptor T‐cell therapy in patients with relapsed or refractory B‐cell malignancies: A meta‐analysis
por: Nguyen, Thi Thuy, et al.
Publicado: (2023)

Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies
por: Mittal, Nivesh K., et al.
Publicado: (2018)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Targeting CD22 as a strategy for treating systemic autoimmune diseases
por: Dörner, Thomas, et al.
Publicado: (2007)

Targets for Ibrutinib Beyond B Cell Malignancies
por: Berglöf, A., et al.
Publicado: (2015)

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
por: Shah, Nirav N., et al.
Publicado: (2019)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
por: Li, Lili, et al.
Publicado: (2022)

A novel anti-CD22 scFv–apoptin fusion protein induces apoptosis in malignant B-cells
por: Agha Amiri, Solmaz, et al.
Publicado: (2017)

Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy
por: Chen, Manling, et al.
Publicado: (2023)

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
por: Qin, Haiying, et al.
Publicado: (2018)

Targeting of CD163(+) Macrophages in Inflammatory and Malignant Diseases
por: Skytthe, Maria K., et al.
Publicado: (2020)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Targeting B cell malignancies through human B cell receptor specific CD4 T cells
por: Weng, Jinsheng, et al.
Publicado: (2015)

MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy
por: Jin, Jin, et al.
Publicado: (2023)

B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20
por: Levy, Michael, et al.
Publicado: (2021)

Targeted Therapies in Adult B-Cell Malignancies
por: Rossi, Jean-François
Publicado: (2015)

Inhibition of the B Cell by CD22: A Requirement for Lyn
por: Smith, Kenneth G.C., et al.
Publicado: (1998)

Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review
por: Bohra, Chandrashekar, et al.
Publicado: (2017)

Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment
por: Juárez-Salcedo, Luis Miguel, et al.
Publicado: (2018)

Identification of CD22 Ligands on Bone Marrow Sinusoidal Endothelium Implicated in CD22-dependent Homing of Recirculating B Cells
por: Nitschke, Lars, et al.
Publicado: (1999)

Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
por: Mannioui, Cécile Schiffer, et al.
Publicado: (2013)

Immunomodulatory Drugs for the Treatment of B Cell Malignancies
por: Ioannou, Nikolaos, et al.
Publicado: (2021)

Complement Activation in the Treatment of B-Cell Malignancies
por: Zent, Clive S., et al.
Publicado: (2020)

Targeting histone deacetyalses in the treatment of B- and T-cell malignancies
por: Zain, Jasmine, et al.
Publicado: (2010)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
por: Lanza, Francesco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bui2av85dhhnm1k0c1a8ohnqsm